– October 1, 2004
October 1, 2004
View Issues
-
Primary Prostate Cancer Management: The Difference at 5 Years
The Prostate Cancer Outcomes Study reports health-related quality-of-life findings 5 years after diagnosis on a cohort of prostate cancer patients who had either initial radical prostatectomy or external beam radiation therapy. Patients who were treated with radiation were more likely to experience rectal discomfort and hemorrhoidal pain, whereas those who were treated surgically suffered a somewhat greater rate of urinary incontinence. -
YKL-40 and Ovarian Cancer
YKL-40 may represent a novel marker for the detection of early stage ovarian cancer. YKL-40 levels in early stage patients may also predict disease recurrence and survival. The use of YKL-40 in detection of early stage ovarian cancer deserves further investigation. -
PET Scanning for Accurate Staging of SCLC
Accurate staging is essential for providing appropriate therapy for small-cell lung cancer because patients with disease confined to one hemi-thorax (limited stage) are treated quite differently that those with more extensive disease at presentation. In the current report from a single institution, the value of pretreatment PET was determined. Of 24 patients considered by conventional imaging studies to have limited disease, two were correctly upstaged on the basis of the PET. -
MRI Breast Cancer Screening for Those at High Risk
Screening techniques for the early detection of breast cancer in women at high risk commonly include clinical breast examination and conventional mammography. In the current report from a single institution, the added value of annual magnetic resonance imaging (MRI) and ultrasound were examined. Among 236 women with BRCA1 or BRCA2 gene mutations, twenty-two cancers were detected. -
Surgical Staging Of Ovarian Low Malignant Potential Tumors
Routine pelvic and para-aortic lymph node dissection is not necessary in the majority of women with ovarian low malignant potential tumors. -
Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer
The levels of circulating tumor cells at baseline and at the first follow-up visit after the initiation of therapy were the most significant predictors of progression-free and overall survival in women with metastatic breast cancer. -
Pharmacology Watch: Linking COX-2 Inhibitors and Cardiovascular Event Risk
Viagra: Maximum Capacity at High-Altitudes?; FDA Actions. -
Clinical Briefs in Primary Care supplement